Beneficio Operativo Cambio Fecha
AstraZeneca USD 2.97B 4.48B 2025-12
Autolus Therapeutics Ltd USD -71.62M 10.99M 2025-09
Hikma Pharmaceutical USD 348M 161M 2025-12
Novartis USD 4.06B 437M 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Silence Therapeutics USD -12.46M 13.78M 2025-12